But now, the FDA has just approved one that helps patients with anemia – a devastating side effect of myelofibrosis. Andrew and Esther Schorr are on a mission – spreading the word about ...

In addition to CK0804, Cellenkos' CK0801 candidate for aplastic anemia has shown promising efficacy, including transfusion independence in treated patients. Myelofibrosis is a rare, chronic, and ...